210 related articles for article (PubMed ID: 16424413)
1. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E; Grootendorst DC; Brightling CE; Troy S; Qiu Y; Zhu J; Parker D; Matin D; Majumdar S; Vignola AM; Kroegel C; Morell F; Hansel TT; Rennard SI; Compton C; Amit O; Tat T; Edelson J; Pavord ID; Rabe KF; Barnes NC; Jeffery PK
Am J Respir Crit Care Med; 2003 Oct; 168(8):976-82. PubMed ID: 12816740
[TBL] [Abstract][Full Text] [Related]
3. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH; Gubb J; Nieman R; Edelson J; Amit O; Bakst A; Ayres JG; Creemers JP; Schultze-Werninghaus G; Brambilla C; Barnes NC;
Lancet; 2001 Jul; 358(9278):265-70. PubMed ID: 11498212
[TBL] [Abstract][Full Text] [Related]
4. Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
Martina SD; Ismail MS; Vesta KS
Ann Pharmacother; 2006 Oct; 40(10):1822-8. PubMed ID: 16985092
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of cilomilast in COPD.
Rennard S; Knobil K; Rabe KF; Morris A; Schachter N; Locantore N; Canonica WG; Zhu Y; Barnhart F
Drugs; 2008; 68 Suppl 2():3-57. PubMed ID: 19105585
[TBL] [Abstract][Full Text] [Related]
6. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
7. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
8. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
Celli B
Chest; 2006 Jan; 129(1):5-6. PubMed ID: 16424403
[No Abstract] [Full Text] [Related]
9. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
[TBL] [Abstract][Full Text] [Related]
10. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA
Br J Clin Pharmacol; 2006 Aug; 62(2):138-52. PubMed ID: 16842388
[TBL] [Abstract][Full Text] [Related]
11. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
12. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
13. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
14. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
Kroegel C; Foerster M
Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of Cilomilast.
Down G; Siederer S; Lim S; Daley-Yates P
Clin Pharmacokinet; 2006; 45(3):217-33. PubMed ID: 16509757
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
Grootendorst DC; Gauw SA; Benschop N; Sterk PJ; Hiemstra PS; Rabe KF
Pulm Pharmacol Ther; 2003; 16(6):341-7. PubMed ID: 14580925
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Poole P; Leung B; Black PN
Cochrane Database Syst Rev; 2011 May; (5):CD002309. PubMed ID: 21563134
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
